Analyst Justin Walsh Reaffirms Buy on TriSalus After Strong Q2 Results, CMS Reimbursement Tailwinds, and Growth Outlook Through 2026
I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Justin Walsh reaffirmed a Buy rating on TriSalus (TLSI) on August 7, citing strong Q2 results, exceeded revenue forecasts, and renewed top-line momentum. The bullish stance is supported by CMS reimbursement tailwinds for TriNav, management's reaffirmed full-year guidance, and anticipated operating expense moderation. Canaccord Genuity also maintained a Buy rating with a $7.00 price target.
JonesTrading analyst Justin Walsh has reiterated their bullish stance on TLSI stock, giving a Buy rating on August 7.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Justin Walsh has given his Buy rating due to a combination of factors including TriSalus’s stronger-than-expected second quarter results and renewed top-line momentum. Revenue exceeded his forecast and management reaffirmed full-year guidance, signaling confidence that the recently expanded salesforce will drive accelerating growth in the back half of 2026.
He also points to favorable reimbursement developments from CMS that should broaden TriNav’s use across care settings and support sustained procedure growth. Coupled with anticipated operating expense moderation and new indications and product upgrades, these dynamics underpin his view that TriSalus’s portfolio can deliver attractive medium- to long-term value relative to the current share price.
In another report released on August 7, Canaccord Genuity also maintained a Buy rating on the stock with a $7.00 price target.